Replies to post #22564 on $Bob's and Jbem's Bitchin' Bios

[BioSpecialist]

More Infos about RDHL

RedHill Biopharma's RHB-104: A Potential Game Changer for Crohn's Disease?
http://www.bionapcfa.com/2015/10/redhill-biopharmas-rhb-104-potential.html

The opportunity for RedHill Biopharma with RHB-104 looks significant. If the Phase 3 trial is successful, I think the market will start to view RHB-104 as having peak sales in the $500-750 million range for the U.S., with potential expansion to over one billion on a global basis.
------

Dan Suesskind , Director
Mr. Suesskind, who served 31 years as CFO of Teva Pharmaceutical Industries (NYSE: TEVA) until 2008, had played a pivotal role in the strategic activities of the Israeli generic pharmaceuticals giant, including the acquisition of more than 30 companies. During that period, Teva grew from a small Israeli company with a market cap of $37 million, into a leading global company with a market cap exceeding $34 billion in 2008. Mr. Suesskind was a member of Teva’s board of directors until recently.

[BioSpecialist]

Great Analysis by J.Napodano he says stock should valued at $500 M ( currently around $150 M includes new shares offering)

RedHill Expects An Eventful Next Few Months
http://www.talkmarkets.com/content/stocks--equities/redhill-expects-an-eventful-next-few-months?post=112761

That being said, I believe RedHill BioPharma is worth approximately $500 million in value today. I see the most valuable asset as RHB-104 for Crohn's disease, followed by RHB-105 for H. pylori infection. Other important assets include Bekinda for gastroenteritis and IBS-D, RHB-104 for MS, and Yeliva and Mesupron in mid-stage development for various oncology indications. The company held $40.5 million in cash as of September 30, 2016, of which I'm including only $25 million into my sum-of-parts analysis. The company has no debt.